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Off label use of medicines is defined as the use of an authorised medicine for a 
purpose or in a manner other than that stipulated  in the summary of product 
characteristics (SmPC) (1), or as approved  by the medicine control council or authirity 
of a country (1).The off label use can be for an unapproved indication, for dose, for 
administering route or, for use in an age group or population not registered during the 
approval process (2). Unregisterd medicines are medications that have not been 
approved for medicinal use in a particular country.(1) The majority of medication 
prescribed to neonates and young infants have not been tested in them and in the 
European Union 45% to 60% of medicine are given to children off label (3 ). In the 
period before 1995 and 2005, only one third of registered medication in Europe were 
approved for use in children (4), while 54% are approved in the United States of 
America (4). An Estonian study demonstrated that 80-98% of drugs used in neonates 
were used off label (5). 
The regulation of modern medicine started only after breakthrough progress in the 
fields of chemistry, physiology and pharmacology (6). This laid a firm basis for 
medicine testing and research. Certain events such as the diethylene glycol poisoning 
and thalidomide induced congenital abnormalities in history, also led to establishment 
of medicine regulatory bodies. In 1937 people in the USA died from diethylene glycol 
poisoning, which was used as a solvent with no prior safety testing and this led to the 
establishment of The Federal Food, Drug and Cosmetics act (6). 
The second important event occurred between 1956 and 1960 and involved the world 
wide use of Thalidomide (6). Thalidomide was developed in Germany in 1956 and was 
used as a hypnotic and sedative. Thalidomide’s widespread use in more than 46 
countries, led to the birth of many babies with phocomelia (6). In 1956, an association 
was made between Sulfonamide antibiotics use, kernicterus and high rates of mortality 
in the premature neonate, this was higher than in infants receiving a tetracycline (7). 
In 1959, a syndrome of sudden cardiovascular collapse was described by Sutherland 
in three neonates who had received high dose chlorompenicol (8).  
Medicine and food regulation bodies were therefore formed worldwide to establish and 
ensure the safety and efficacy of new medicines, and especially to protect public safety 
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(6). More recent defining events were the adverse events noted in low birth weight 
babies who were exposed to parenteral vitamin E  (9), a gasping syndrome in those 
neonates who received excessive doses of benzyl alcohol (10), as well as the roles of 
maternal retinoic acid and anti-depressants and their link to anomalies in the embryo 
and fetus. These events affecting the young infant and child, have led to more 
conservative medicine use and choices by perinatologists, neonatologists and 
paediatricians (11). 
After discovery of a new medicine formulation by a pharmaceutical company, the 
pharmaceutical company claims temporary legal rights to the formulation (11). 
Medicine development includes pre-clinical trials, which determine the effects of 
systemic administration and tolerance, where the chemical formulation is tested on 
cells and whole tissue prior to testing on animals (12). The medicinal formulation is 
then taken through further testing phases. 
For a medicine to be ideal for children, it needs to be suitable for the age, the 
physiological condition and body weight of the child being treated (13). Furthermore, 
the medicine needs to be available in an appropriate form, such as a  solid form that 
can either be taken whole or sprinkled, or a dissolvable form that can be mixed in 
solution and taken as a liquid mixture or syrup (13).  
According to the World health Organisation (WHO), shortage of medicines is a 
worldwide problem which mostly affects the developing countries (13). There is a 
worldwide shortage of appropriate medication for children, which unfortunately affects 
the developing world more profoundly(14). According to The World Health 
Organisation (WHO), millions of children under five years of age die from diseases 
that could have been treated had the “ideal medication” been available(14). In 
December 2007, the World Health Organisation (WHO) launched a campaign called 
“Make medicines child size” which raised awareness about improving availability of 
safe, effective and quality medicines for children(14). This initiative was to affect all 
sectors ranging from government to pharmaceutical companies that are involved in 
developing and procurement of medicines for children(14). Access to appropriate 
medicines for children is essential in achieving the World Heath Organisation’s 
Sustainable development Goals (SDGs), which in 2015 replaced the previous 
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Millenium Development goals(15,16). MDG 4 and MDG 6 were replaced by SDG 3, 
where SDG 3.1  aims “By 2030, end preventable deaths of newborns and children 
under 5 years of age, with all countries aiming to reduce neonatal mortality to at least 
as low as 12 per 1000 live births and under 5 mortality to at least as low as 25 per 100 
live births” and SDG 3.2 targets that “by 2030, end the epidemics of AIDS, 
tuberculosis, malaria and neglected tropical diseases and combat hepatitis, 
waterborne diseases and other communicable diseases” (15,16)  
Many medicines in children are used “off label” as there is not enough clinical evidence 
or trials done on children to support their safety and efficacy therefore, these 
medicines cannot be registered for paediatric use. The WHO has published guidelines 
called “Development of paediatric medicines: points to consider in pharmaceutical 
formulation”. These guidelines seek to provide the ideal children’s medication as 
stated above, to be suitable for the age, physiological condition and the child’s body 
size (14). The WHO assistant Director-General for health technology, Dr Howard 
Zucker said in Geneva in 2007, “We need to learn more about the way children’s 
bodies react to medicines so we can improve global child health. That’s why it’s 
extremely important to keep track of potential side effects in child populations. 
Ultimately, this will save lives and build up a knowledge base for the future” (14) 
A wide range of medication prescribed for paediatric patients is done so without any 
formal study and most are off-label for use in this population (17). Treatment decisions 
are usually based on the prescriber’s clinical experience, observational studies and at 
times, extracted from adult data (17, 18). As noted above, this is done because of 
shortage of clinical evidence. Use of off label or unregistered medication had been 
linked with paediatric adverse side effects, more than registered medication (17). A 
study done in Swedish hospitals found that the highest proportion of off-label 
prescriptions occurred in neonates and infants, 41% of all authorised medicines during 
the study were given off-label (17). The same study also classified intravenous 
electrolyte substitutions and carbohydrates as ‘off-label’ as these products were at 
times used for oral administration though intended for parenteral use(17) 
In Europe, the majority of medicines used in paediatrics, have not been studied in this 
age group and have not been approved by the European Medicines Evaluation 
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Agency (EMEA) for use in this population (19). Greater caution is needed when 
prescribing medication for the younger and smaller patient as it may not be appropriate 
to make decisions based on data gathered from older children and adults (20). 
Neonates often have different reactions to administered medicines compared to 
adults, they have unique and rapidly evolving physiological characteristics.(20) Of 
importance is the understanding of pharmacokinetics, which studies the fate of the 
medicine as it passes through the living object and Pharmacodynamics which is the 
link between the dose of the product and its effect on the organism to which it has 
been administered to (21).  A thorough understanding of human developmental 
biology and an understanding of the dynamic processes of medication absorption, 
medicine distribution, metabolism and excretion, is the only way that will lead to a more 
specific approach to neonatal therapeutics.   
Children are not small adults but have their own unique physiology, which changes 
with age groups (22). Neonates and young children have hepatic and renal immaturity 
which often results in low clearance, inadequate detoxification and the long half-life of 
particular medicines (20). The various age groups within the peadiatric population itself 
are not only different in terms of their physical size but,  there are also biochemical 
differences which affect how drugs are metabolized and eliminated via the kidney (22). 
The pharmacodynamics are marked in the first week of life in a pre-term neonate. The 
neonate and the young child  have higher body water percentage compared to adults, 
lower proportions of adipose tissue and another difference is that of lower muscle 
mass (23). An example of the difference in medicine metabolism is that of 
chloramphenicol in the neonate, this was metioned previously as a cause of high 
mortality in neonates (22). Studies show increased concentrations of chloramphenicol 
and its metabolites in the blood of neonates (22). This accumulation is a result of the 
inadequate process of metabolizing chloramphenicol by glucoronidation, which is age 
dependent (22). The half life of chloramphenicol varied amoung the age groups, with 
a half life of twenty six hours in the neonate, ten hours in the infant, and four hours in 
children (22) Glucuronidation is an  important factors in pharmacokinetics (22). The 
Allometric approach can be used to somewhat predict elimination of medicine but 
because of lack of accuracy in different age groups, it can not replace clinical 
pharmacokinetic studies (22). .  
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The percutaneous barrier is another difference,  where the premature neonates has a 
more thinner percutaneous barrier (stratum corneum) compared to the term neonates 
(24, 25). Neonates also have increased blood flow to the skin in comparison to adults 
(24). This affects the amount of medicine absorbed through the skin and the resultant 
higher systemic availability when compared to the same dose given in adults, where 
absorption is minimal (26). The pharmacodynamics and kinetics change with maturity, 
with alteration in protein binding, volume of distribution, renal and hepatic clearance 
as these systems mature (22). There are also differences between various ages 
regarding gastric and intestinal emptying time and gastric pH. For absorption to occur, 
the medication given by extra-vascular route has a number of chemical and 
physiological steps through which it must go (18). Bio-availability of the substance is 
affected by changes that occur in the developing gastro- intestinal tract. (18, 20). In a 
sick individual, physiological changes that occur during illness also affect the 
absorption of medication. 
 
The oral route is the route of choice whenever appropriate (18). The pH of the stomach 
contents affects the bio-availability of the medicine (21). The gastric pH changes over 
time. At birth, it is neutral, decreasing during the first day of life. On the tenth day of 
life, the pH would have returned to the neutral state (27, 28). In terms of volume of 
gastric acid secreted, the volume is equal to that of adults by the age of three years 
(29). By three years of age, the pH is also similar to that of adults (29). These changes 
therefore render the paediatric patient far different to the adult in that medicines that 
are affected negatively by gastric pH are absorbed better (29). There is decreased 
absorption of weak organic acids, some medicines are absorbed more readily and 
rapidly than in the adult (29). Premature babies differ in that the initial pH changes do 
not occur in the first fourteen days of life. Gastric emptying in adults occurs in two 
phase, while in premature infants it occurs in a slower and linear rate. Gastric emptying 
occurs at the rate of an adult, only by six to eight months of age (21,27, 7). Time taken 
for intestinal transit, is longer in neonates. This is due to the reduced motility and 
reduced peristalsis (30). Other differing factors, are immaturity of digestive fluid 
secretion (21), intestinal mucosa prematurity (28), high intestinal levels of the enzyme 
beta-glucuronidase activity (28), a reduction in amount of first pass metabolism (21), 
and variable microbial colonization (21). 
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A complex amount of developmental processes which are both physiological and 
biochemical occur during the growth process (31,21). A study done on the effect of 
phenorbabital in the neonate undergoing thermal therapy also found that the above 
factors were more important in predicting the clearance of medicines(32). This early 
period of development entails changes in the volume of distribution, enzymatic activity, 
elimination pathways, and other variables that change over time (32). 
 
During the first few months of life, there is rapid development in both physiological and 
biochemical processes, this therefore means that during this time, there is rapid 
change in medicine pharmacokinetics (31). With these changes it suffices to say that 
in prolonged therapy in the neonate for example, a neonate being treated for sepsis 
on day one of life, the pharmacokinetics at the beginning of the treatment, will be very 
different after two weeks of treatment with the same medicine (31). 
 
There are two phases of medicine metabolism (22). Phase I, is the small structural 
alterations that occur which aid in the renal excretion by decreasing the lipophylicity of 
the medicine (22).  Phase II “involves the conjugation of a functional group on the 
molecule with hydrophilic endogenous substrates” Involved in this phase are the 
processes called acetylation, glucoronidation and sulfation (22).  The liver is the most 
important organ for medicine metabolism, even though so biological transformation 
occurs in Intestine, skin, kidney and lung (33). Metabolism of some medication, for 
example, Ibuprofen, requires the Cytochrome P450 complex, components of this 
system are the CYP2C8 and the CYP2C9 systems, traces of these compounds have 
been found to be present in the newborn who is younger then one day (34). These 
amounts increase slowly over the first few weeks of life, to reach half the adult quantity 
by the time the child is one month of age (34). An example of differing 
pharmacokinetics is that of isoniazide in the neonate, where neonates were found to 
have decreased absorption and decreased clearance, this was also noted in the 
neonate of younger gestational age (35). However, a study of ibuprofen in neonates 
with a Patent ductus arteriosus had different findings, suggesting that the 
pharmacokinetics of the ibuprofen were not affected by the gestational age (34) 
 
Generally, most medicines in neonates have a prolonged elimination half-life (35). A 
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few studies have been conducted to study clearance variability in the neonate (36). 
One of the studies published in 2005 was based on the clearance of Aminoglycosides, 
particularly amikacin in neonates. It suggested that the major role players in clearance 
variability in the extreme premature neonate are the size and post-conceptual age, 
this therefore raises the need to know target concentrations of amikacin so as to 
reduce the variability in clearance (36). There is anecdotal suggestion that amikacin 
is less nephrotoxic in the neonate, as a result of reduced renal uptake capacity (36). 
The study group hypothesized that the Clearance of medicines and GFR, were also 
affected by medication given to the mother in the prenatal period, an example of this 
was the associated rise in GFR at birth in mice that had been given Betamethasone 
prenatally (36).The clearance of some medication, for example, phenobarbital was 
found to have a proportional increase with age (32). In the neonate, kidney maturity 
controls the pharmacokinetics of some medicines such as penicillin, cephalosporins 
and aminoglycodides (37). In preterm infants, there is reduction in the excretion and 
clearance when compared to term infants, the clearance of the above medicines is 
increased with advanced neonatal gestational age and maturation (37).  Yet again, 
isoniazide is an example of differing pharmacokinetics in the smaller and younger 
patient, where it goes through intensive first pass metabolism (35). Medication 
elimination rate then, depends on the maturity of the Cytochrome P450 hepatic 
enzyme system, immaturity of the liver and therefore the liver enzymes will impair the 
elimination of the medication in the more premature and younger low birth weight 
infant (35). Another known fact is that of a decreased half-life as the age increases, 
this supports that there is slower elimination of isoniazide in the young child (35)  
 
Children may have different  reactions to medication and the medicine’s ingredients 
when compared to adults (34). Ingredients contained in the medicines given to adults 
may not necessarily be safe to give to neonates but, medicines that were developed 
for adults are used in this valnurable age group (34). Attention to the needs of the 
neonate population, needs to be made a priority in making safe and appropriate 
medicines (38). There are a number of reasons why conducting clinical trials in 
children as a whole is difficult (3). Ethical issues  arise in choosing the type of 
randomized control trial to conduct for off label medicines in neonates, these relate to 
Study design, Subject enrolment, informed consent and data analysis (39). The 
following is discussion of some of these issues:  There are a number of concerns 
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regarding the present use of off label medicines in neonates without understanding 
their efficacy and risk, the risks in neonates are higher as this is a critical period of 
development, associated with fetal programming effect(39). The question therefore, is 
whether randomized control trials should be done in neonates or whether to continue 
without being fully aware of safety, pharmacokinetics and efficacy of the medicines we 
choose. 
The Belmont report in 1979 recommended, “Special protection for research involving 
vulnerable subjects and children”(39). According to the American federal regulations, 
there are ethical conditions that need to be satisfied before a review board can approve 
research, the regulations are based on risk, benefit and the likelihood of yielding 
generalisable knowledge (39). The most important aspect mentioned in the Belmont 
report, which is important in children is “the benefit issue” the prospect of direct benefit 
(39). In conducting randomized control trials, the trial needs to be designed in a way 
that minimizes risks and maximizing benefits (39). There are two types of research 
designs that are usually used in neonates, active control trials and placebo control 
trials. Active control trials (ACT), use active controls with equal allocation. Placebo 
controlled trials (PCT), use placebo with equal allocations (39). Ethics in ACT, involves 
a comparator rather than placebo. ACTs decrease the risks to the participants and 
establishes the equivalence or non-inferiority of a new treatment, compared with a 
tandard treatment (Active control) (39). 
PCT, is most commonly used as it determines efficacy and safety. It requires the 
subject over a shorter period (39). Ethically, a PCT is only justified if no standard 
treatment exists, if it exists, then the PCT is only justified if  no evidence of efficacy or 
safety has been established; an example of this, was the study of caffeine in neonates 
(caffeine studies have been published in many countries where Caffeine is not 
registered, unlike in South Africa). However, PCT in life threatening conditions cannot 
be justified (39). 
Enrolment of subjects poses another ethical issue. Obligation for enrolment consent 
lies on the treating doctor or the person doing the study. The doctor is obliged to offer 
the parents an opportunity to enroll the baby in the study. The person doing the study 
needs to share existing evidence for or against the medicine and compare to other 
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available treatment (39). Studies done within the first twenty four hours of life need 
antenatal notification or consent (39). 
According to a paper published at George Washington University in 2005, only 2.8% 
of medicines studied were registered for use in the neonates (11). Between 1995 and 
1998, out of the 45 medicines registered by the European Medicine evaluation agency, 
29 of these had potential use in the neonate or child, but only 10 of these was actually 
registered for use. Therefore, 33% of potentially useful medicines were licensed for 
neonates (11). Between January 1995 and September 2001, 1380 medicines were 
registered in Europe, 1157 of these had potential use in children and neonates, but 
only 339 of these were licensed for all children, 257 of them were on-label because of 
age and weight groups only (11). These show a drop rather than an increase in use of 
registered medicine, or rather, emphasizes the fact that the amount of studies 
undertaken for the registering of medicines has decreased (11). 
Of interest also are studies that were done to look at the nature of unregistered 
medicine use and also in which areas of the healthcare system were these medicines 
being used. A study in the neonatal intensive care units in the United Kingdom showed 
that within a period of 13 weeks in 1999, 70 patients received medication, of whom 49 
were premature and 21 were term neonates (11). In that study,  A total of 455 
prescriptions were written for the neonates and 45 medicines (10%) of the medicines 
prescribed were not registered. The unregistered medicines most commonly used in 
that neonate group was caffeine (11). In the Netherlands, over a 5 week period in 
2001, 62% of the prescribed medication was unregistered, with caffeine again being 
the most frequently used un-registered medication in that study(11). 
A study done in Turkish neonatal intensive care units, showed that within a period of 
24 hours, of the 1315 prescriptions written up, comprising 93 medicine formulations, 
62.3% of the medication given to the neonates were un-registered or off- label (40). 
A similar study in Germany showed that 61% of all paediatric patients in Germany 
received at least once in their lives, off label medication. Another study, actually 
compared use of off label medication between neonates and older children. This study, 
showed that, off label medication use, was about 80-97% in NICU as opposed to 36-
92% in the Paediatric Intensive care unit (40). 
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The use of unregistered and off label medication in neonates cannot be avoided as it 
is often necessary to treat medical conditions in neonates. This does not in any way 
show negligence or poor medical practice as there are often no registered alternative 
medications that can be used (11). Furthermore, many countries like the United States 
and Turkey have in their legislation made room for doctors to prescribe, pharmacy to 
dispense and for nurses to administer un-registered and off label medication when 
there are no existing alternative options(36,11). 
Although there is a lot of concern regarding the use of un-registered and off label use 
of medicines in neonates, information relating to the extent of this use in South Africa 
is very limited and for this reason this study was undertaken (41,36).  
Aims and objectives 
The aim of the study is to determine the off label and unregistered use of medicines in 
neonates admitted to Tygerberg Hospital..  
Primary Objectives 
1. To identify the magnitude off-label and unregistered medicines prescribed in
the general neonatal wards over a 3-month period.
2. To assess whether these medicines where used off-label for dose, route of
administration, indication or frequency.
Methodology 
Setting: 
Tygerberg Hospital is a tertiary care hospital situation in the Western Cape South 
Africa. It serves as a referral hospital for approximately half of the Western Cape 
Province. The Division of Neonataology is situated within the Department of 
Paediatrics and Child Health and admits approximately 300 neonates to the neonatal 
intensive care unit and the neonatal wards. This research project was conducted within 
3 neonatal wards excluding the neonatal intensive care unit. 
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Type of study: 
This is a prospective descriptive study  
Duration of the study: 
The study was conducted over a 3 month period (August to November 2013) 
Population studied: 
     Inclusion criteria: 
• All neonates (0-28 days old) admitted to the three neonatal wards and
who received medicines during the admission.
     Exclusion criteria 
• Neonates older than 28 days old
• Neonates admitted to the neonatal intensive care unit.
• Neonates who did not receive any medicines during admission.
Data collected and analysis 
This was a prospective descriptive survey done over a three months period 
investigating all medicine scripts of neonates admitted in the study period. Data 
collected included age, clinical diagnosis, weight on admission and medicines 
prescribed including dose, formulation, indications and frequency. Excluded from 
prescription records were Intravenous fluid replacement solutions, mineral 
supplements, blood products and oxygen therapy. The data (textual and numerical) 
was captured on a computerised format using a spreadsheet on an IPAD. The data 
was then be analysed using the medicine package insert pamphlet and the South 
African Medicines Formulary 2014 and the MIMS (Monthly index of medical 
specialties) to determine whether they were prescribed appropriately, or off label or 
unregistered. Registered medication was further subdivided into off label groups, 
namely, off label for dose, for indication, for frequency, for route of administration, for 
lack of data or contraindicated in the age group.  
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 A unique study number was assigned to each patient record and this list was kept 
separate from data capture sheet, where data was collected linked to the unique study 
number. Data analysis was anonymous using only this unique study number.  
Statistical analysis  
Descriptive data was analysed reported as means and standard divisions where the 
data was evenly distributed or otherwise as medians and interquartile ranges. In 
comparisons between groups Chi square analysis was used.   
Ethical considerations: 
Ethics approval was granted by the Human Research Ethics Committee, Stellenbosch 
University (no: S13/07/130, main study N11/07/215). Waiver of consent was requested 





There were 168 patients enrolled in the study. The male to female ratio was 1:1.2. The 
majority, namely 112 neonates ( 67%) were born prematurely, and 56 (33%) were full 
term babies.  
Figure 1: Representation of birth weight categories.  
Nearly half (45%) of the preterm neonates had a low birth weight, 32% had a very low 
birth weight, 23% had an extremely low birth weight.  Of the term neonates, 35% were 
born with a low birth weight, 2% with a very low birth weight and 63% weighed more 
than 2500 grams. The grouped weights had a mean weight of 2.35 kg (median 2.0 kg; 
standard deviation of 0.978) for the study population. 
Diagnoses: 
 The number of diagnoses per admitted neonate ranged between 1 and 7  with a mean 
of 4 diagnoses per neonate. The primary diagnoses were respiratory distress of the 
newborn (RDS) in 20%, hyaline membrane disease (HMD) in 14%, prematurity 













hyperbilirubinemia/neonatal jaundice (NNJ) in 9% and potential risk of sepsis in 8.5%. 
Less common diagnoses were perinatal asphyxia (3%) , anaemia (3%), twin delivery 
(3%) and preterm premature rupture of membranes (3%). The other 26.5% of the 
diagnoses included hypoglyceamia (2%), intra-uterine growth retardation (2%), 
syphilis exposure (2%), feed intolerance (2%), transient tachypnea of the newborn 1%, 
cardiac defects 1% and thrombocytopenia 0.6%. (see chart 3)  
HIV INFECTION EXPOSURE 
One hundred and twenty three (73%) of the babies were HIV-unexposed , while 44 
(26%) were exposed to HIV and one whose exposure was unknown (0.5%). All HIV-
exposed infants, as well as those of the mother’s whose HIV status was unknown, 
started on antiretroviral (ARV) prophylaxis. The ARV prophylaxis included nevirapine 
(n=44, 98%) and 1 was started on zidovudine (2%).   
MEDICINES  
There were 810 medicine events recorded from 168 neonates, which included 59 
different medicines. Mineral supplements were included. Excluded were blood 
products and intravenous fluids. The range of medicines prescribed per neonate 
varied from 1 to 14, with an average number of 5 medicines prescribed to each study 
patient.  
The majority of the medicine events (98.5%) involved registered medicines, with 1.5% 
not registered in South Africa. The unregistere medicines were intravenous 
phenorbarbitone (8 prescriptions) and chloral hydrate (1 prescription). Both these 
medicines required a section 21 application form to be filled in.  A section 21 form is a 
form required by SAHPRA for authorization of use of an unregistered medication.  .  
The majority (85%;n=692) of the medicine events were off label. There was no 
extemporaneous use of any medicine in neonates during the study period. The 
number of off label drug events per neonate ranged from 1 to 15 with an average of 5 
off label events per neonate. There was an average of 5 off label events in the 
premature group, while the term group had an average of 3 off label events per 
neonate. The majority (48%; n=391) of the off label prescriptions were for age, while 
44% (n=356) for frequency, 37% (n=296) were off label for weight and 29% (n=236) 
off label for indication.  In less than 2% of patients,  the medicine was prescribed off 
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label for route and in 0.4%, off label for lack of data. Less than 1% (0.7%; n=6) involved 
medicines contraindicated in neonates. The reasons for off-label use per medication 
were analysed in groups and these often overlapped. The percentages portrayed were 
calculated for each group out of the 810 events. 
FLOW CHART 1: GRAPHIC REPRESENTATION OF REGISTRATION AND 


























TABLE 1: The ten most commonly prescribed medicines 
Medicine Frequency of prescription 
events 
Percentage 
Penicillin G 109 13.5% 
Gentamycin 104 12.9% 
Aminophylline BD  97 12.0% 
Aminophylline stat  83 10.3% 
Caffeine 56 6.9% 
Nevirapine 44 5.4% 
Vitamin D 38 4.7% 
Meropenem 27 3.3% 
Glycerine suppository 23 2.9% 
Atropine 21 2.6% 
 
The most commonly prescribed medicines were Penicillin G (109 events) 13.5% and 
Gentamycin (104) 12.9%. These were used as the first line of antibiotic therapy for all 
neonates with confirmed or suspected sepsis. This was followed by aminophylline as 
a twice daily dose (n=97) 12.0% and aminophyilline as a single dose (n=83) 10.3%, 
Caffeine (a registered medicine) was prescribed for (n=56) 6.9% neonates. These 
three agents are prescribed for neonates weighing less than 1500g to prevent apnoea 
of prematurity. Nevirapine was prescribed for 44 neonates (5.4%) exposed to Human 
immunodeficiency virus in-utero. A small number (n=38; 4.7%) received vitamin D. 
Only 4% received meropenem, followed by Glycerine suppositories in 3% and atropine 
in 2.9%. Atropine was used for premature neonates with hyaline membrane disease 
for prevention of bradycardia during intra-tracheal incubation. Vidaylin and 
vancomycin prescriptions made up 2.6% each. The combination of meropenem and 
vancomycin were second line antibiotic therapy for neonates with sepsis. The 
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surfactants were prescribed for neonates admitted to the general neonatology wards 
with hyaline membrane disease: Curosurf (15) 2%, and Survanta (1.2%). Doxapram 
was prescribed in 1.5%. 
Six most common off label medicines and reasons for off label use. 
Medicine No. of prescriptions Reason for off label 
status 
Aminophylline stat 83 (10%) Indication, age, weight 
for dose 
Aminophylline 12 hourly 97 (12%) Age, Indication 
frequency and duration 
Nevirapine 44 (5.4%) Off-label for age and 
weight for dose 
Meropenem 27 (3%) Age and frequency 
Chlorhexidine 7 (0.8%) Age, frequency and 
duration 
Azithromycin 3 (0.4%) Age, weight, dose and 
duration  
 
As demonstrated in flow diagram 1, 85% of the prescription events were off-label. The 
off-label events for each medication ranged from a single to 3 off label events. 
Intravenous aminophylline as a single or 12 hourly dose had the most off label events. 
Single dose aminophylline was used off label for indication, age, and weight for dose. 
As a twelve hourly dose, it was off label for age, indication, frequency and duration. 
Other medication that had 3 or more reasons for off-label classification were 
Azithromycin and Perfalgan.  Nevirapine which is widely used for prevention of mother 
to child transmission of HIV was off label for age, and weight for dose. The package 
insert had a dose (per kilogram of weight) for children from the age of two months, 
there were no guidelines for prescribing to neonates. Although it is indicated for 
prevention of transmission, it is only registerd for use from 2 months of age.    
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Table 3  demonstrates all the medicines (48) prescribed in the study. It excludes 
mineral supplements, and classifies the medicines according to the World health 
organisation’s Anatomical Therapeautic Chemical Classification System (ATC). It also 
tabulates and the drug events (753). Included on the table are medicines that are not 
registerd for use, those that are registered,and the reason for off label classification, if 
any are noted.  
Table 3: Drug categories according to ATC Classification 




of  drug 
events 
Criterion of 
off label use 
Proton pump inhibitors A02BC Omeprazole 1 
 Age, weight 
for dose, no 
paediatric 
data 
Enema A06AG Glycerine suppository 23 
Age, Weight 
for dose. 
Multivitamines A11B Vi-daylin 19  Age, weight for dose. 
Vitamin D and analogues A11CC Vitamin D 38 None 
Vitamin K B02BA Vitamin K 4 Weight for Dose,  
     
 C Cardiac  therapy         
Atropine C01E Atropine 21 Age, weight for dose 




Silicone and zinc products D02AA Zinc and castor oil ointment 2  
Antibiotics D06A Bactroban ( mupirocin) 8  
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J01EE Cotrimoxazole 1 Frequency, dose 
Beta-lactamase resistant 




Benzylpenicillin 1  
  Benzylpenicillin (Pen G) 109  
Lincosamides J01FF Clindamycin           1  
Aminoglycosides J01GB 
Amikacin 1   
Genatmycin        104  




           3 Frequency, 
dose 
Drugs for treatment of 
tuberculosis: Antibiotics J04AB Isoniazide 2 Dose 
J05 Antivirals         
Nucleosides and 
nucleotides excl. reverse 
transcriptase inhibitors 
J05AB Acyclovir 2   
Nucleoside and nucleotide 
reverse transcriptase 
inhibitors 
J05AF Zidovudine (AZT) 1 Frequency, dose 
Non-nucleoside reverse 
transcriptase inhibitors J05AG Nevirapine 44  
Triazole derivatives J02AC Fluconazole 3  
Specific immunoglobulins J06BB Tetanus immunoglobulin 1   
Immunoglobulin, normal 
human, for intravenous 
administration 
J06BA02 Polygam 8  
Bacterial vaccines J07AM Tetanus toxoid 1  
Choline derivatives M03AB  Suxamethonium 1   
Other general anesthetics N01AX Ketamine 3   
Aldehydes and derivatives N05CC Chloral hydrate 1 Unregistered 
Xanthine derivatives N06BC Caffeine 56  
Other opioids N02AX Tilidine (valoron) 1 Age, dose 
Anilides N02BE Paracetamol (oral) 3 
Age, dose, 
frequency 
 N02BE Paracetamol (IVI Perfalgan) 6  








  Phenobarbitone (oral) 1  
Xanthines R03DA Aminophylline (Once off) 83  
 R03DA Aminophylline (12 Houly) 97  







Lung surfactants R07AA 
Poractant alfa 
(curosurf) 15  
Beractant 
(Survanta) 9  
Antibiotics S01AA Chloramphenicol 4  




A great number of studies have been done internationally that documented the 
prevalence and side effects of a range of medications used in the neonate and child, 
with very few studies from Africa (41). Off label use was a highly prevalent problem in 
healthcare, with rates of up to 90% reported for neonatal intensive care units 
(42).There were no studies available prior to this study, that divide the neonatal group 
based on gestational age and birth weights. That is unique to this study.  
 
The off label use in neonates in this study was unexpectedly high (86%) if compared 
to a similar study in the European Union which reported a range of OL events of 46-
60% (4). However, a study done in Estonia reported that 87% of all prescribed 
medicines to neonates were off label (490 neonates were included, with the majority 
of prescriptions being antibiotics, medicines for the central nervous system and 
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cardiovascular system  (5). There was at least one off label medication prescribed per 
neonate in the Estonian study (5), which was similar to our study.   
As noted in the article reviews, a wide range of medicines formulations were used in 
neonates,  mostly off label, since there was little knowledge regarding the dose, 
formulation, and evidence of safety and efficacy (5). As mentioned, the preterm infant 
was even more vulnerable than the term neonate due to a further reduction in excretion 
and clearance when compared to term infants (39). Off label use of medication in the 
neonate is often a necessity as there is a lack of clinic trials that provide safety and 
efficacy data (13).  
 
The most common prescribed medicines in this study were Penicilling G and 
Gentamycin, both antibiotics, which were similar to findings in the Estonia study, where 
antibiotics were more common (42)  
 
The prescribed 1.5% of unregistered medicines in this study was low in comparison to 
a number of studies done worldwide. When compared to other low- to middle income 
contries, a Palestinian study reported a higher rate of 7.1% (42). Studies in France 
and the United Kingdom showed rates of 10%, In Italy 12% and rates of 14% in the 
Netherlands (42). A study in Europe reported that only 34% (66% unregistered) of 
potentially neonatal medicines were registered (13). The most commonly prescribed 
medication that was unregistered in the Netherlands was caffeine (13), which is a 
registered medication in South Africa,and also used as approved by the South African 
Health Products Regulatory Authourity (SAHPRA) 
 
 
The most common reason for off- label use in this study was age, with 48% of the 
prescribed medication being used off-label for the neonatal patient. Of note was the 
most frequently used off-label for age medication which was Nevirapine with 49 
prescription for all HIV-exposed infants. Nevirapine is only recommended for use from 
the age of 2 months by the South  African package insert, although, there was a 
recommended dose per kilogram of weight. Human immunodeficiency virus is a great 
cause of morbidity and mortality in Africa. South Africa has a high prevalence of HIV 
infection with the number of people living with HIV in 2011 was 6.3 million, in 2015, 
the number had increased to nearly 7 million (43). The 2015 National Antenatal 
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Sentinel HIV and Syphillis Survey Report showed a HIV prevalence of 30.8% among 
women attending antenatal care clinics (43). The prevalence of HIV among pregnant 
women aged 15-24 years was 19.2% in 2015 (43). One hundred and ninety seven 
(24.5%) of the studied medication were prescribed to neonates who had HIV-infected 
mothers.  
 
Off-label for frequency was second at 44.2%, this was for aminophylline which was 
given intravenously, every twelve hours. The most commonly used off-label for 
indication was also aminophylline, which was different from the findings in a Turkish 
study where  Erythromycin and Ibuprofen were reported to be the most common 
medicines used off label for indication (36).  The third highest reason for of label use 
was weight-for-dose, the use of Atropine. As previously mentioned, the World Health 
Organisation’s guidelines recommended medication that is suitable for age, 
physiological condition and the child’s body size (18), this recommendation was not 
adhered to in this insatnce. Atropine was the most used in this off-label manner, which 
was consistent with the findings in the Turkish study, that found that many of the 
registered medications were being used on neonates,  at a higher dose then was 
recommended by the product pamphlet or leaflet (36).  The least common off-label 
classifications were off-label for route, contraindicated and off-label for lack of data, at 
1.6, 0.7 and 0.4% respectively, which differed from the Turkish study that found that 
the most common reason for off label use was no data or lack of information(36). A 
Netherlands study found caffeine to be most common medicine used off label, 
whereas this study found the most common medicine to be aminophylline (22%) as 
caffeine is registered in South Africa for use in neonates. The off label use of the 
antiviral nevirapine was second at 5.4%, followed by the antibiotics for systemic use, 
meropenem, at 3%. This differ from studies in Estonia, Australia and India where 
antibiotics were found the most common off label prescribed medicines (4,5) 
 
The study group included 79% of medicine events for pre-term neonates with 
respectively  birth weights from extreme low birth weight (<1000g)(ELBW) in 26%, 
35% had very low birth weight (<1500g) and 38% had a low birth weight of less than 
2500g, which was comparable to the  study  done in the United Kingdom (15). There 
was a big gap of knowledge in medication for this group of pre-term infants as they 
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are definitely not “small adults” though treatment decisions are often based on 
observational studies and often extracted from adult data (18, 19). 
 
Conclusion 
The off-label drug use in neonates was high in this study population, indicating the 
need for dedicated clinical trials in neonates. At the same time, the outcomes after the 
use of off label medicines in neonates should be published to generate knowledge 
about the safety and efficacy of the medicines in neonates.  
 
There are only a few such studies published in South Africa, and  although this study 
only confirms what is already known by people in the academic medical settings, there 
are still large learning opportunities in the greater medical and pharmaceutical field. 
Much more work still needs to be done to encourage awareness amongst doctors and 
nurses who care for this valnurable population. Healthcare workers need to be more 
aware of what and how they are prescribing medication, that off-label status of 
medicines means that there is no data to suggest that the medicine they are 
prescribing on a daily basis to neonates has been tested by the company that 
produced it, on the neonatal group.   
 
Looking at the outcomes of this study that was done in a big Southern African Tertiary 
institution, it is important to put it in context. Busy Southern African hospitals often do 
not have the capacity to despence to the large numbers of patients that are born daily, 
on an  individual basis or script. Large neonatal units such as this order medication 
from the pharmacy often in bulk, which is then kept as ward stock. In this manner, 
there is no room for pharmacists to assess and question the script based on the 
patient’s age, weight and the medicines labelling and  registration status. This then 
removes a step in the control of the prescription of these medications. Further, as 
previously mentioned, there are no available alternates that are based on clinical trials 
rather then based on the experience of the clinician.    
 
One of the great limitations of this study was the time taken to analyse the collected 
data, and in that time, opportunity for a follow up study looking at the long term side 
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effects or long term effects of the medicine that was prescribed to the neonates either 
off-label or unregistered was lost.   
     
One of the greatest achievements recently in neonatal pharmaceutics was the 
registration of Caffeine for use in neonates either orally or intraveneously. This 
significantly affected the outcomes of the study as previously, caffeine was the most 
widely used un-registered  medicine in neonates. This proves that the health and 
safety of the neonate is being considered and much greater care is being taken in 
making medicines child safe.    
 
Doctors, nurses and pharmacists need to be aware of the labelling and registration of 
medication. They all need to be aware that these medicines that they use daily may 
not be illegal to use, but whether they are really safe in the long run is not known.  I 
hope that with this study, I will encourage health care workers to ask more questions 
with each medicine they prescribe and administer to each neonate, is it safe, is it 
appropriate is it registered for use. I further hope that with that, more pressure will be 
felt by pharmaceutical companies to develop novel ways of doing ethical studies on 
neonates and therfore develop safer medications for the valnurable neonate with 
evidence base to support the use of such medicines.  
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